Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IDYA

Ideaya Biosciences Inc

Dec 26 • 02:37PM ET

25.80

Dollar change +0.50
Percentage change 1.98	%

Healthcare • Biotechnology • USA • NASD

Peers: EXEL INCY NBIX BPMC ARGX FATE YMAB NERV GOSS ENTA

| Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA VHT LABU

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.33	Insider Own	10.43%	Shs Outstand	86.36M	Perf Week	0.82%
Market Cap	2.23B	Forward P/E	-	EPS next Y	-2.72	Insider Trans	0.00%	Shs Float	77.42M	Perf Month	-2.79%
Income	-178.12M	PEG	-	EPS next Q	-0.63	Inst Own	99.54%	Short Float	11.72%	Perf Quarter	-15.41%
Sales	3.92M	P/S	568.86	EPS this Y	-25.73%	Inst Trans	12.43%	Short Ratio	9.98	Perf Half Y	-24.94%
Book/sh	13.67	P/B	1.89	EPS next Y	-10.28%	ROA	-20.09%	Short Interest	9.08M	Perf Year	-27.22%
Cash/sh	10.64	P/C	2.42	EPS next 5Y	-	ROE	-21.10%	52W Range	24.48 - 47.74	Perf YTD	-27.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.95%	ROI	-14.85%	52W High	-45.95%	Beta	0.80
Dividend TTM	-	Quick Ratio	22.93	Sales past 5Y	14.24%	Gross Margin	-7.44%	52W Low	5.41%	ATR (14)	1.30
Dividend Ex-Date	-	Current Ratio	22.93	EPS Y/Y TTM	-19.54%	Oper. Margin	-5729.08%	RSI (14)	44.39	Volatility	5.60% 5.02%
Employees	124	Debt/Eq	0.02	Sales Y/Y TTM	-83.30%	Profit Margin	-4540.40%	Recom	1.14	Target Price	55.79
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-31.47%	Payout	-	Rel Volume	0.22	Prev Close	25.30
Sales Surprise	-74.00%	EPS Surprise	7.36%	Sales Q/Q	-100.00%	Earnings	Nov 04 BMO	Avg Volume	909.55K	Price	25.80
SMA20	-2.55%	SMA50	-7.99%	SMA200	-28.19%	Trades		Volume	156,336	Change	1.98%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Initiated	Stephens	Overweight	$51
Nov-05-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27
Oct-24-24	Initiated	UBS	Buy	$50
Oct-15-24	Initiated	Cantor Fitzgerald	Overweight
Jul-08-24	Initiated	Mizuho	Outperform	$50
Mar-08-24	Initiated	BTIG Research	Buy	$55
Aug-08-23	Initiated	SVB Securities	Outperform	$33
May-24-23	Initiated	Goldman	Buy	$32
Apr-24-23	Upgrade	Stifel	Hold → Buy	$18 → $24
Mar-23-23	Initiated	Berenberg	Buy	$26
Feb-28-23	Initiated	RBC Capital Mkts	Outperform	$25
Dec-28-22	Initiated	CapitalOne	Overweight	$29
Oct-27-22	Initiated	Citigroup	Buy	$26
Aug-15-22	Downgrade	Stifel	Buy → Hold	$16 → $13
Jul-18-22	Resumed	Oppenheimer	Outperform	$25
Mar-10-22	Upgrade	Stifel	Hold → Buy	$27 → $20
Sep-23-21	Initiated	Stifel	Hold	$27
Jun-04-21	Resumed	Robert W. Baird	Outperform	$28
Mar-11-21	Initiated	Guggenheim	Buy	$32
Oct-07-20	Initiated	Wedbush	Outperform	$21

Show Previous Ratings

Dec-17-24 06:00AM	IDEAYA Announces IDMC Recommendation of Move-Forward Dose in Part 2a of Registration-Enabling Trial of Darovasertib and Crizotinib Combination in 1L HLA-A2-Negative Metastatic Uveal Melanoma (PR Newswire)
Dec-16-24 06:00AM	IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers (PR Newswire)
Dec-11-24 06:00AM	IDEAYA Announces Agenda for Investor RandD Day Webcast on December 16, 2024 (PR Newswire)
06:00AM	IDEAYA Announces Agenda for Investor R&D Day Webcast on December 16, 2024 (PR Newswire)
Dec-10-24 06:00AM	IDEAYA Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE161 in Combination with KEYTRUDA (pembrolizumab) in Patients with Endometrial Cancer (PR Newswire)
06:00AM	Loading…
Dec-09-24 06:00AM	IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor (PR Newswire)
Dec-06-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +5.38%
Dec-02-24 06:00AM	IDEAYA Biosciences Announces Participation in Upcoming December 2024 Investor Relations Events (PR Newswire)
Nov-29-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Nov-22-24 07:33AM	Ideaya Biosciences Inc. (IDYA): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-18-24 06:00AM	IDEAYA Biosciences Appoints Stu Dorman as Chief Commercial Officer (PR Newswire)
Nov-12-24 06:00AM	IDEAYA Biosciences Announces Participation in Jefferies London Healthcare Conference and Plans for Investor R&D Day (PR Newswire)
Nov-11-24 06:00AM	IDEAYA Announces Development Candidate Nomination of IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise with Biocytogen (PR Newswire)
06:00AM	Biocytogen Announces IDEAYAs Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise (Business Wire)
Nov-07-24 09:55AM	Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know (Zacks)
08:30AM	Loading…
Nov-04-24 08:30AM	IDEAYA Biosciences, Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
08:30AM	/C O R R E C T I O N -- IDEAYA Biosciences, Inc./ (PR Newswire)
Nov-01-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-29-24 10:01AM	Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline (Zacks)
Oct-28-24 06:00AM	IDEAYA Biosciences Announces IND-Clearance for Werner Helicase Development Candidate IDE275 (GSK959) for a Phase 1 Study in MSI-High Solid Tumors (PR Newswire)
Oct-25-24 06:00AM	IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024 (PR Newswire)
Oct-04-24 06:00AM	IDEAYA Biosciences Announces Late-Breaker Oral Presentation of IDE397 Phase 1 Expansion Results in MTAP-Deletion Lung and Urothelial Cancer at the 36th Edition of the EORTC-NCI-AACR Symposium (PR Newswire)
Sep-27-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-24-24 08:13AM	IDEAYAs rare cancer drug shows promise as company lays out Phase III plans (Clinical Trials Arena) -7.00%
Sep-23-24 06:00AM	IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma (PR Newswire)
Sep-22-24 09:00AM	IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024 (PR Newswire)
Sep-18-24 06:00AM	IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel (PR Newswire)
Aug-30-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-26-24 06:00AM	IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (PR Newswire)
Aug-23-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
01:54PM	Loading…
Aug-06-24 01:54PM	IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q2 2024 (InvestorPlace)
06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Aug-01-24 10:01AM	IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-31-24 06:00AM	IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen (PR Newswire)
06:00AM	Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program (Business Wire)
Jul-29-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event (PR Newswire)
Jul-23-24 09:55AM	How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97% (Zacks)
Jul-11-24 04:05PM	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) +6.16%
Jul-09-24 10:26PM	IDEAYA Announces Pricing of Public Offering (PR Newswire)
04:08PM	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
01:49PM	IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data (Zacks)
06:54AM	Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Jump Turn into More Strength? (Zacks)
06:52AM	IDEAYA Biosciences reports positive data from Phase II trial of cancer treatment (Clinical Trials Arena)
Jul-08-24 04:15PM	Why Ideaya Biosciences Just Made Its Most Bullish Move Since March (Investor's Business Daily) +15.32%
12:57PM	Top Stock Movers Now: Intel, Corning, SolarEdge, and More (Investopedia)
12:08PM	IDEAYA Biosciences Soars on Cancer Drug Study Results (Investopedia)
06:00AM	IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer (PR Newswire)
Jul-05-24 04:05PM	IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024 (PR Newswire)
Jun-28-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jun-26-24 07:13AM	IDEAYA Biosciences initiates subject dosing in Phase I bladder cancer trial (Clinical Trials Arena)
Jun-25-24 06:00AM	IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy Combination in MTAP-Deletion Bladder Cancer (PR Newswire)
Jun-24-24 06:00AM	IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors (PR Newswire)
Jun-03-24 06:00AM	IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study (PR Newswire) +6.40%
May-31-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
May-29-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events (PR Newswire)
May-28-24 06:00AM	IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development (PR Newswire)
May-23-24 09:21PM	IDEAYA Biosciences Announces Abstract Summary Results of ASCO 2024 Oral Presentation for Phase 2 Investigator Sponsored Study of Darovasertib in Neoadjuvant Uveal Melanoma (PR Newswire) -7.08%
09:21PM	/C O R R E C T I O N -- IDEAYA Biosciences, Inc./ (PR Newswire)
May-16-24 05:57PM	Ideaya Biosciences Insider Sold Shares Worth $7,397,291, According to a Recent SEC Filing (MT Newswires)
May-08-24 08:47AM	Oppenheimer Adjusts IDEAYA Biosciences Price Target to $53 From $50, Maintains Outperform Rating (MT Newswires)
May-07-24 01:54PM	IDYA Stock Earnings: IDEAYA Biosciences Misses EPS for Q1 2024 (InvestorPlace)
10:23AM	IDEAYA Biosciences Shares Fall After Q1 Loss (MT Newswires)
07:35AM	IDEAYA Biosciences Inc (IDYA) Reports Q1 2024 Earnings: Financial and Strategic Developments (GuruFocus.com)
06:00AM	IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-01-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event (PR Newswire)
Apr-26-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-24-24 10:05AM	IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study (PR Newswire)
Apr-22-24 06:00AM	IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer (PR Newswire)
Apr-05-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-01-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event (PR Newswire)
Mar-27-24 09:25AM	TipRanks Perfect 10 List: These 3 Top-Scoring Stocks Are Sending a Bullish Signal (TipRanks)
Mar-12-24 06:00AM	IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA (pembrolizumab) in Patients with Endometrial Cancer (PR Newswire)
Mar-04-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events (PR Newswire)
Feb-20-24 06:36AM	IDEAYA Biosciences Q4 Results Misses Estimates (RTT News) -6.62%
06:00AM	IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (PR Newswire)
Feb-13-24 05:37AM	IDEAYA Biosciences Inc CEO Yujiro Hata Sells 99,372 Shares (GuruFocus.com)
Feb-01-24 06:00AM	IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events (PR Newswire)
Jan-26-24 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Jan-18-24 01:03AM	IDEAYA Biosciences Inc President and CEO Yujiro Hata Sells 75,000 Shares (GuruFocus.com)
Jan-15-24 07:03AM	IDEAYA Biosciences, Inc. (IDYA) Moves 7.6% Higher: Will This Strength Last? (Zacks)
Jan-07-24 09:00AM	IDEAYA Biosciences Announces Participation at the 42nd Annual J.P. Morgan Healthcare Conference and 2024 Corporate Guidance (PR Newswire)
Dec-29-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-08-23 06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-05-23 06:00AM	IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event (PR Newswire)
Dec-04-23 06:00AM	IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy and IDE397 Combination in MTAP-Deletion Bladder Cancer (PR Newswire)
Dec-03-23 09:00AM	IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023 (PR Newswire)
Nov-14-23 09:55AM	Can IDEAYA Biosciences, Inc. (IDYA) Climb 25.48% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-07-23 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
06:44AM	IDEAYA Biosciences Inc (IDYA) Reports Q3 2023 Financial Results and Business Update (GuruFocus.com)
06:00AM	IDEAYA Biosciences, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire)
Nov-01-23 06:00AM	IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Jefferies London Healthcare Conference (PR Newswire) +6.33%
Oct-27-23 04:02PM	IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire) -5.51%
06:00AM	IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Oct-25-23 11:55AM	Why Ideaya Biosciences Stock Is Plummeting Today (Motley Fool)
Oct-24-23 10:15PM	IDEAYA Announces Pricing of Public Offering (PR Newswire)
04:07PM	IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (PR Newswire)
Oct-23-23 06:00AM	IDEAYA Announces Top-Line Phase 2 Results at ESMO 2023 of Darovasertib and Crizotinib Combo in MUM, and Clinical Efficacy Updates for Neoadjuvant UM, GNAQ/11 Cutaneous Melanoma, and Synthetic Lethality Pipeline (PR Newswire) +5.54%
Oct-18-23 08:33AM	IDEAYA Biosciences, Inc. (IDYA) Surges 7.6%: Is This an Indication of Further Gains? (Zacks)
Oct-17-23 06:00AM	IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023 for Phase 2 Clinical Data Update for Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma (PR Newswire) +7.60%
Oct-16-23 06:00AM	IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma (PR Newswire)

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jason Throne	Former Officer	Aug 26 '24	Proposed Sale	40.22	75,000	3,016,500		Aug 26 05:16 PM
Throne Jason	Chief Legal Officer	Jun 27 '24	Option Exercise	7.77	53,484	415,587	63,484	Jun 27 06:47 PM
WHITE MICHAEL ANTHONY	Chief Scientific Officer	May 29 '24	Option Exercise	12.86	28,500	366,510	28,500	May 31 04:26 PM
WHITE MICHAEL ANTHONY	Chief Scientific Officer	May 29 '24	Sale	36.24	28,500	1,032,884	0	May 31 04:26 PM
Hata Yujiro S	President and CEO	May 15 '24	Option Exercise	4.31	83,856	361,419	761,743	May 16 05:51 PM
Hata Yujiro S	President and CEO	May 14 '24	Option Exercise	4.31	56,711	244,424	734,598	May 16 05:51 PM
Hata Yujiro S	President and CEO	May 16 '24	Option Exercise	4.31	34,433	148,406	712,320	May 16 05:51 PM
Hata Yujiro S	President and CEO	May 15 '24	Sale	42.90	83,856	3,597,756	677,887	May 16 05:51 PM
Hata Yujiro S	President and CEO	May 14 '24	Sale	41.61	56,711	2,359,780	677,887	May 16 05:51 PM
Hata Yujiro S	President and CEO	May 16 '24	Sale	41.81	34,433	1,439,754	677,887	May 16 05:51 PM
Ruiz Briseno Andres	See Remarks	Feb 09 '24	Sale	46.02	2,000	92,045	24,531	Feb 13 04:59 PM
Hata Yujiro S	President and CEO	Feb 08 '24	Option Exercise	4.31	75,815	326,763	753,702	Feb 12 04:27 PM
Hata Yujiro S	President and CEO	Feb 09 '24	Option Exercise	4.31	23,557	101,531	701,444	Feb 12 04:27 PM
Hata Yujiro S	President and CEO	Feb 08 '24	Sale	45.15	75,815	3,422,835	677,887	Feb 12 04:27 PM
Hata Yujiro S	President and CEO	Feb 09 '24	Sale	45.54	23,557	1,072,715	677,887	Feb 12 04:27 PM
Hata Yujiro S	President and CEO	Feb 01 '24	Option Exercise	4.31	628	2,707	678,515	Feb 05 06:05 PM
Hata Yujiro S	President and CEO	Feb 01 '24	Sale	45.00	628	28,260	677,887	Feb 05 06:05 PM
Ruiz Briseno Andres	See Remarks	Jan 22 '24	Sale	42.03	2,000	84,050	26,531	Jan 24 07:12 PM
Ruiz Briseno Andres	See Remarks	Jan 12 '24	Sale	38.01	2,000	76,026	28,531	Jan 17 05:41 PM
Hata Yujiro S	President and CEO	Jan 16 '24	Option Exercise	4.31	62,739	270,405	740,626	Jan 17 05:40 PM
Hata Yujiro S	President and CEO	Jan 12 '24	Option Exercise	4.31	12,261	52,845	690,148	Jan 17 05:40 PM
Hata Yujiro S	President and CEO	Jan 16 '24	Sale	40.17	62,739	2,519,968	677,887	Jan 17 05:40 PM
Hata Yujiro S	President and CEO	Jan 12 '24	Sale	40.04	12,261	490,913	677,887	Jan 17 05:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IDYA

Ideaya Biosciences Inc

Upgrade your FINVIZ experience